Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Akas Jain

Reproductive Endocrinology Westerville, OH Medical Doctor

NPI 1215017785 CMS profile 281548

540 N. Cleveland Ave, Suite 100, Westerville, OH 43082

Open in the dashboard

General payments

$4,882

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Akas Jain of Westerville, OH is reported in the CMS Open Payments database as having received $4,882 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $511 13
2024 General $879 24
2023 General $466 23
2022 General $453 26
2021 General $799 40
2020 General $434 20
2019 General $1,339 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Akas Jain
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Akas Jain were reported at $511. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Akas Jain Reproductive Endocrinology median Middle half National median
2019 $1,339 $196 $77–$425 $163
2020 $434 $81 $35–$182 $114
2021 $799 $102 $43–$247 $132
2022 $453 $139 $62–$303 $149
2023 $466 $141 $65–$285 $160
2024 $879 $144 $65–$302 $164
2025 $511 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $1,076 59 payments
  2. CooperSurgical, Inc. $619 22 payments
  3. Hologic, LLC $474 9 payments
  4. Ferring Pharmaceuticals Inc. $470 31 payments
  5. Merck Sharp & Dohme Corporation $398 22 payments
  6. EMD Serono, Inc. $326 26 payments
  7. Myovant Sciences Inc. $269 10 payments
  8. Medical Device Business Services, Inc. $217 2 payments
  9. AbbVie, Inc. $184 5 payments
  10. Sage Therapeutics, Inc. $160 1 payment
  11. Other $688 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,870 203 payments
  2. Education $11 1 payment
Products named General payments · program years 2019–2025
  1. PREGNYL $865 47 payments
  2. GANIRELIX ACETATE $719 36 payments
  3. FOLLISTIM AQ Follitropin $668 34 payments
  4. MENOPUR $409 28 payments
  5. FOLLISTIM AQ Womens Health $398 22 payments
  6. MYFEMBREE $269 10 payments
  7. Novasure $254 4 payments
  8. STRIPPER $206 5 payments
  9. Myosure $176 2 payments
  10. Gonal-f $160 15 payments
  11. Other $2,225 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record